Clinical trial · Observational
D1 vs D2 Lymphadenectomy in Gastric Cancer
Prognostic Implications of D1 vs D2 Lymphadenectomy in Gastric Cancer: a Propensity Score Matched Analysis
NCT05253430CI-TRIAL-00056686completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a retrospective study with a propensity score-matched analysis in order to balance differences between patients with D1 and D2 lymphadenectomy for gastric cancer.The main aim is to analyse differences in the postoperative and oncological outcomes of patients with gastric cancer (GC) who underwent D1 and D2 gastrectomy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lymphadenectomy type | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- D1 lymph node dissection (LND)
- description
- Patients with gastric cancer that underwent curative surgery with gastrectomy and D1 lymph node dissection
- label
- D2 lymph node dissection (LND)
- description
- Patients with gastric cancer that underwent curative surgery with gastrectomy and D2 lymph node dissection
- interventionNames
- Procedure: Lymphadenectomy type
Primary outcomes (1)
- measure
- Disease-free survival
- timeFrame
- percentage of patients without disease recurrence alive at 3 and 5 years after surgery
- description
- Disease-free survival (DFS) was defined as the time from gastric surgery to the date of recurrence (locoregional, peritoneal recurrence and/or distant metastases).
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients diagnosed with GC stage I-III who underwent a curative gastrectomy +/- perioperative chemotherapy Exclusion Criteria: * patients with adenocarcinoma Siewert type I/II, palliative surgery, R1/R2 resections and pathological stage (pStage) IV.
References
Publications (0)
Data not yet available
No reference posted for this study.